News Extra [these Stories Appear Only On The Web]

New England journal report describes unique features of adverse reactions in TGN1412 trial

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7568.570-a (Published 14 September 2006) Cite this as: BMJ 2006;333:570
  1. Susan Mayor
  1. London

    The healthy volunteers who took part in the clinical trial of the anti-CD28 monoclonal antibody TGN1412 had multiple organ failure similar to that seen in septic shock but with several unique features, says a report published last week by Dr Suntharalingam and his colleagues, who cared for the six men after they were transferred to the NHS (New England Journal of Medicine 2006;355:1018-28).

    Within 90 minutes of receiving a single intravenous dose of TGN1412 all six volunteers had a systemic inflammatory response characterised by a rapid …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe